Composition of matter

Claim 2

A pharmaceutical composition of matter useful as a topical medicament which comprises a therapeutically effective amount of a water unstable E-type prostaglandin compound, 2-10% of emulsifying wax, N.F., and 80-95% of a plasticizer.

Claim 3

The pharmaceutical composition of matter according to claim 1, wherein the active ingredient is 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester.

Claim 4

The pharmaceutical composition of matter according to claim 1, wherein the emulsifying wax is a mixture of higher fatty alcohols and ethylene oxide reaction products.

Claim 5

The pharmaceutical composition of matter according to claim 1, wherein the plasticizer is triethyl citrate.

Claim 6

A pharmaceutical composition of matter useful as a topical medicament which comprises a therapeutically effective amount of a water unstable E-type prostaglandin compound, 10-20% of emulsifying wax, N.F., 70-90% of mineral oil and 5-20% of diisopropyl adipate.

Claim 7

A pharmaceutical composition of matter useful as a topical medicament which comprises a therapeutically effective amount of a water unstable E-type prostaglandin compound, 10-20% of emulsifying wax, N.F., 70-90% of mineral oil and 5-20% of diisopropyl adipate.

Claim 8

The pharmaceutical composition of matter according to claim 5, wherein the active ingredient is 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester.

Claim 9

The pharmaceutical composition of matter according to claim 5, wherein the emulsifying wax is a mixture of higher fatty alcohols and ethylene oxide reaction products or equal parts of a mixture of 75% cetostearyl alcohol/25% ethoxylated cetostearyl alcohol and a mixture of 75% stearyl alcohol/25% ethoxylated cetostearyl alcohol.

Claim 10

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of dissolving the water unstable E-type prostaglandin compound in the plasticizer by heating at 45°-70° C. on a steam bath together with the emulsifying wax until a clear solution is obtained, and cooling to room temperature.

Claim 11

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of dissolving the water unstable E-type prostaglandin compound in the plasticizer by heating at 45°-70° C. on a steam bath together with the emulsifying wax until a clear solution is obtained, cooling to room temperature, and adding absolute ethanol.

Claim 12

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of dissolving 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester in triethyl citrate by heating at 45°-70° C. on a steam bath together with the emulsifying wax until a clear solution is obtained, and cooling to room temperature.

Claim 13

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of dissolving 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester in triethyl citrate by heating at 55° C. on a steam bath together with the emulsifying wax until a clear solution is obtained, and cooling to room temperature.

Claim 14

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of mixing on a steam bath at 45°-70° C. individually heated on a steam bath at 45°-70° C. clear solutions of the emulsifying wax and the plasticizer containing the E-type prostaglandin compound until a clear solution is obtained, and cooling to room temperature.

Claim 15

A method of making a pharmaceutical composition of matter according to claim 1, comprising the steps of mixing on a steam bath at 55° C. individually heated on a steam bath at 55° C. clear solutions of the emulsifying wax and triethyl citrate containing 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester until a clear solution is obtained, and cooling to room temperature.

Claim 16

A method of making a pharmaceutical composition of matter according to claim 5, comprising the steps of mixing together the emulsifying wax and mineral oil on a steam bath at 45°-70° C. until a clear solution is obtained, dissolving the E-type prostaglandin compound in the diisopropyl adipate on a steam bath at 45°-70° C., mixing the emulsifying wax/mineral oil mixture with the diisopropyl adipate containing the active ingredient on a steam bath at 45°-70° C. until a clear solution is obtained and cooling to room temperature.

Claim 17

A method of making a pharmaceutical composition of matter according to claim 5, comprising the steps of mixing together the emulsifying wax and mineral oil on a steam bath at 55° C. until a clear solution is obtained, dissolving 7-[2β-(4-butyl-4-hydroxy-1,5-hexadienyl)-3α-hydroxy-5-oxo-1.alpha.-cyclopentyl]-5-heptenoic acid, methyl ester in the diisopropyl adipate on a steam bath at 55° C., mixing the emulsifying wax/mineral oil mixture with the diisopropyl adipate containing the active ingredient on a steam bath at 55° C. until a clear solution is obtained and cooling to room temperature.